Pharmaceutical Executive Daily: FDA Names Seven Participants to Precheck Program

June 30, 2026 11:04am 3 min

In today's Pharmaceutical Executive Daily, FDA selects seven companies for its new PreCheck Pilot Program, Kirsten Whipple examines how the concept of healthspan is emerging from academic obscurity into a powerful consum...

Pharmaceutical Executive Daily: Ipsen Enters Merger Agreement to Acquire Kartos Therapeutics

June 29, 2026 12:45pm 3 min

In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers Ipsen's up to $1.75 billion acquisition of Kartos Therapeutics and Zymeworks' $929 million acquisition of Theravance Biopharma, Krista Pinto of Evers...

Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

June 25, 2026 12:51pm 3 min

Pharmaceutical Executive Daily: Eli Lilly and Abbisko Announce Drug Development Collaboration

June 24, 2026 2:58pm 3 min

In today's Pharmaceutical Executive Daily, Eli Lilly and Abbisko Therapeutics announce a new strategic research collaboration in which Abbisko will leverage its early-stage drug discovery platform to advance targets sele...

Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts

June 23, 2026 2:50pm 3 min

In today's Pharmaceutical Executive Daily, the FDA announces Operation TrialBlazer, a pilot program aimed at cutting early-stage clinical trial timelines by six to 12 months as the US looks to reclaim its footing in glob...

Pharmaceutical Executive Daily: AbbVie Acquires Apogee Therapeutics for $10.9 Billion

June 22, 2026 1:58pm 3 min

In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding a suite of clinical-stage immunology assets to its portfolio, Insilico Medicine enters an AI-po...

Pharmaceutical Executive Daily: FDA Advisory Committee Votes Unanimously in Favor of The Benefit-Risk Profile of Moderna's mRNA-1010

June 19, 2026 11:02am 3 min

In today's Pharmaceutical Executive Daily, an FDA advisory committee votes unanimously in favor of the benefit-risk profile of Moderna's investigational mRNA-1010 seasonal influenza vaccine across both younger and older ...

Pharmaceutical Executive Daily: FDA Approves Utebzi and Capvaxive

June 18, 2026 1:51pm 3 min

In today's Pharmaceutical Executive Daily, Biogen announces its second acquisition of 2026, a deal worth up to $1 billion for private immunology biotech RayThera, FDA approves Utebzi as the first and only oral carbapenem...

Pharmaceutical Executive Daily: Meaningfully Improving Therapy Persistence in Patient Support Programs

June 17, 2026 12:05pm 3 min

In today's Pharmaceutical Executive Daily, FDA staff release briefing documents flagging evidence gaps in Moderna's mRNA flu vaccine, a pharma roundup covers Merck's $510 million collaboration with Protillion Biosciences...

Pharmaceutical Executive Daily: FDA has Approved Skinvive by Juvéderm

June 16, 2026 2:10pm 4 min

In today's Pharmaceutical Executive Daily, Elicio Therapeutics shares tumble after its Phase II Amplifgy-7P trial of KRAS-targeting immunotherapy ELI-002 7P misses its primary endpoint in adjuvant pancreatic cancer, FDA ...

Pharmaceutical Executive Daily: FDA Approves Two Indications of Keytruda in Combination with Welireg

June 15, 2026 12:23pm 3 min

In today's Pharmaceutical Executive Daily, Boehringer Ingelheim's Brian Hilberdink argues that obesity innovation must evolve beyond the scale, a pharma regulatory roundup covers two significant FDA approvals, and Pharma...

Pharmaceutical Executive Daily: Kardigan Sets Terms for $350 Million IPO

June 12, 2026 11:34am 3 min

In today's Pharmaceutical Executive Daily, Kardigan sets terms for a $350 million IPO that would value the cardiovascular biotech at approximately $1.3 billion, Pharmaceutical Executive speaks with Rick Winningham on bui...

Pharmaceutical Executive Daily: China's Latest Policy Guidance

June 11, 2026 1:46pm 3 min

In today's Pharmaceutical Executive Daily, Bruce Liu examines China's latest policy guidance establishing premium pricing and priority reimbursement access for truly innovative drugs, Parabilis Medicines surges more than...

Pharmaceutical Executive Daily: Parabilis Medicines Prices Record-Breaking $670 Million IPO

June 10, 2026 2:06pm 2 min

In today's Pharmaceutical Executive Daily, Parabilis Medicines prices a record-breaking $670 million IPO, Swedish biotech AlzeCure Pharma enters a collaboration and out-licensing agreement with Eli Lilly for its Alzheime...

The Ron Lanton Report: From Innovation to Infrastructure

June 10, 2026 5:00am 7 min

In this episode, Ron Lanton draws on insights from the JP Morgan Healthcare Conference to explain how healthcare investment is shifting from backing novel ideas to funding organizations that can scale, survive regulatory...

Pharmaceutical Executive Daily: GSK Acquires Nuvalent for $10.6 Billion

June 09, 2026 12:44pm 3 min

In today's Pharmaceutical Executive Daily, a pharma funding roundup covers two RNA-focused biotechs that secured fresh capital, GSK announces a $10.6 billion agreement to acquire Nuvalent in its largest deal in over a de...

Pharmaceutical Executive Daily: Roche and Nurix Therapeutics Announce Global Collaboration

June 08, 2026 2:36pm 4 min

In today's Pharmaceutical Executive Daily, Roche and Nurix Therapeutics announce a global collaboration, a pharma M&A roundup covers three deals announced today, and Pharmaceutical Executive contributors examine how an e...

Pharmaceutical Executive Daily: Supreme Court Unanimously Rules in Favor of Hikma Pharmaceuticals in Skinny Label Case

June 05, 2026 11:48am 2 min

In today's Pharmaceutical Executive Daily, the Supreme Court unanimously rules in favor of Hikma Pharmaceuticals in its patent dispute with Amarin over Vascepa, Pfizer licenses Chai Discovery's generative AI platform, an...

Pharmaceutical Executive Daily: Alnylam Pharmaceuticals and Inceptive Nucleics Announce 3 Year Strategic Collaboration

June 04, 2026 1:51pm 3 min

In today's Pharmaceutical Executive Daily, Eli Lilly escalates its 340B enforcement standoff by notifying covered entities of a five-business-day window to submit required claims data or lose access to 340B pricing, Alny...

Navigating PBM Pitfalls: Protecting Revenue in a Complex Rebate Landscape

June 04, 2026 8:00am 35 min

In this episode of Pricing & Policy with Model N, Jesse Mendelsohn, senior vice president at Model N, joins host Mike Christel to offer a candid, expert-driven look at the pharmacy benefit manager (PBM) landscape, includ...